Understanding the distinct drivers of insulin resistance informs more targeted therapies and investment in interventions—such as free‑fatty‑acid modulation and microbiome support—that could deliver sustainable metabolic improvements beyond temporary diet effects.
The discussion centers on two distinct pathways to insulin resistance: the metabolic derangement that accompanies excess body fat and the physiological insulin resistance observed during very low‑carbohydrate, ketogenic eating patterns. Robert Eckel explains that a ketogenic diet suppresses insulin, drives massive fatty‑acid flux from adipose tissue, and forces the liver to produce ketone bodies, creating a transient, starvation‑like insulin‑resistant state.
Key data points include the observation that fatty acids remain elevated throughout the day in keto participants, supporting continuous ketogenesis. While low‑carb regimens often yield rapid weight loss and favorable lipid shifts—triglycerides drop and HDL initially falls—the advantage erodes after one to three years as weight stabilizes and insulin sensitivity reverts. In contrast, obesity‑related insulin resistance is fueled by chronic free‑fatty‑acid excess, leading to high triglycerides, low HDL, and impaired hepatic glucose suppression.
Eckel highlights that insulin’s impact extends beyond glucose handling: it stimulates aldosterone production, raises cortisol, and in conditions like polycystic ovarian syndrome directly amplifies androgen synthesis. He also references a 15‑day study of 38 Terra’s Daily Microbiome Nutrition, which boosted short‑chain fatty acid output and beneficial microbes, suggesting gut health may modulate metabolic risk.
For clinicians and investors, distinguishing these mechanisms matters. Short‑term keto may be a useful weight‑loss tool, but lasting metabolic health likely requires addressing free‑fatty‑acid flux, hormonal sequelae, and gut‑microbiome balance rather than relying solely on carbohydrate restriction.
Comments
Want to join the conversation?
Loading comments...